1.0Public Citizenhttps://www.citizen.orgMegan Whitemanhttps://www.citizen.org/author/mwhiteman/rich600338<blockquote class="wp-embedded-content" data-secret="SPQnKFSUJq"><a href="https://www.citizen.org/article/colombia-access-to-medicines/">Colombia – Access to Medicines</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.citizen.org/article/colombia-access-to-medicines/embed/#?secret=SPQnKFSUJq" width="600" height="338" title="“Colombia – Access to Medicines” — Public Citizen" data-secret="SPQnKFSUJq" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript"> /* <![CDATA[ */ /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); /* ]]> */ </script> For nearly two decades, Colombian activists, experts and academics have been fighting to expand equitable access to medicine across the country by deliberately challenging pharmaceutical monopoly power. In the latest effort, Global Humanitarian Progress Corporation (GHP Corp) and Public Citizen, along with more than 120 other organizations and prominent individuals worldwide, voiced strong support for the Ministry of Health’s move to authorize price-cutting generic competition with the critical patented AIDS drug dolutegravir.https://www.citizen.org/wp-content/uploads/Screenshot-2023-07-13-at-9.18.14-AM-1024x558.png1024558